What is SpliceBio?
SpliceBio is at the forefront of developing advanced gene therapies, leveraging its proprietary Protein Splicing platform. This technology is designed to overcome a critical limitation in current gene therapy methods: the inability of traditional adeno-associated virus (AAV) vectors to deliver large genes. By enabling the delivery of these larger genetic payloads, SpliceBio aims to unlock new therapeutic avenues for a range of inherited retinal diseases, a significant unmet medical need. The company's base in Barcelona, Spain, positions it within a growing European biotech hub.
How much funding has SpliceBio raised?
SpliceBio has raised a total of $191M across 2 funding rounds:
Series A
$56M
Series B
$135M
Series A (2022): $56M with participation from UCB Ventures, Gilde Healthcare, New Enterprise Associates, and Ysios Capital
Series B (2025): $135M led by Ysios Capital, Novartis Venture Fund, EQT, ROCH Ventures, Asabys Partners, Gilde Healthcare, New Enterprise Associates, Sanofi Ventures, and UCB Ventures
Key Investors in SpliceBio
Ysios Capital
Ysios Capital is a leading life sciences venture capital firm that invests in highly innovative biotechnology companies worldwide. The firm provides biotech ventures with the necessary resources to develop novel therapies aimed at addressing significant unmet medical needs.
Novartis Venture Fund
The Novartis Venture Fund invests in innovative life science companies focused on biotechnology and biopharmaceutical therapeutics that address unmet patient needs. With over USD 750 million in committed capital, the fund supports a diverse portfolio of more than 40 companies across North America and Europe.
UCB Ventures
UCB Ventures is a strategic corporate venture fund focused on investing in early-stage companies in the US and Europe that develop innovative therapeutic modalities and technologies. The fund seeks breakthrough innovations in areas such as cell and gene therapy, regenerative medicine, and RNA modulation.
What's next for SpliceBio?
With the recent substantial capital injection, SpliceBio is poised for a period of accelerated growth and development. The company is expected to advance its pipeline of gene therapies through critical clinical trials, aiming to validate the efficacy and safety of its Protein Splicing platform. Strategic partnerships and further research into expanding the platform's applicability to other genetic conditions are also anticipated. This funding round, characterized as a major strategic investment, signals a strong belief in SpliceBio's potential to disrupt the gene therapy market and deliver life-changing treatments for patients with inherited retinal diseases.
See full SpliceBio company page
